Trial · NCT01807949
Adverse events1,506
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,506
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo | 82 | 186 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 69 | 186 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 56 | 187 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | Placebo | 47 | 186 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 40 | 186 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 29 | 187 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo | 15 | 186 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 32 | 186 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 31 | 187 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | Placebo | 26 | 186 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 28 | 186 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 20 | 187 | |
| other | Nasal congestion | Respiratory, thoracic and mediastinal disorders | Placebo | 19 | 186 | |
| other | Nasal congestion | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 24 | 186 | |
| other | Nasal congestion | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 13 | 187 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Placebo | 20 | 186 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 20 | 186 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | LUM 400 mg q12h/ IVA 250 mg q12h | 13 | 187 | |
| other | Respiration abnormal | Respiratory, thoracic and mediastinal disorders | Placebo | 13 | 186 | |
| other | Respiration abnormal | Respiratory, thoracic and mediastinal disorders | LUM 600 mg qd/IVA 250 mg q12h | 14 | 186 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01807949/events